Guggenheim lowered the firm’s price target on MBX Biosciences (MBX) to $77 from $84 and keeps a Buy rating on the shares following Q3 earnings. The firm, which reiterates “Top Pick Designation” as MBX advances towards a catalyst-rich 2026, updated its model for Q3 results and the September financing, which drives its price target change.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MBX: